SGLT2 inhibitors and heart failure — clinical implications

Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy

(2015) Richard E Gilbert et al.   LANCET

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

(2013) H. J. Lambers Heerspink et al.   DIABETES OBESITY & METABOLISM

Hemoconcentration is a good prognostic predictor for clinical outcomes in acute heart failure: Data from the Korean Heart Failure (KorHF) Registry

(2013) Jaewon Oh et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization

(2010) Husam M. Abdel-Qadir et al.   AMERICAN HEART JOURNAL

Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

(2009) B Komoroski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS